In a phase 3 trial, researchers from the University of Toronto in Toronto, Canada, evaluated the safety and efficacy of sotagliflozin in adults with type 2 diabetes and stage 3 chronic kidney disease. The primary objective was the superiority of HbA1c reductions at week 26 with sotagliflozin compared to placebo. At 26 weeks, the placebo-adjusted mean change in HbA1c was -0.1% and -0.2% in the sotagliflozin 200 and 400 mg groups, respectively, indicating a significant reduction. Urine albumin creatinine ratio was also reduced with both doses, but changes were not sustained at week 52. Adverse events, including serious adverse events, were comparable between the treatment groups.
Today: November 30, 2023